Company news
Myriad Genetics, Inc. (NASDAQ:MYGN) news
Myriad Genetics, Inc. news releases on 6ix. Latest, Sep 16, 2026: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Press releases & updates
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
September 16, 2026
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
August 27, 2026
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
July 30, 2026
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
July 23, 2026
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
July 21, 2026
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
July 1, 2026
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
June 23, 2026
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
June 2, 2026
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
May 27, 2026
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
May 26, 2026
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
May 15, 2026
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
May 7, 2026
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
May 5, 2026
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
April 30, 2026
ProgenyHealth Announces New Appointments to Company Leadership Board and Executive Team
April 29, 2026
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
April 28, 2026
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
April 16, 2026
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
April 13, 2026
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
April 8, 2026
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
March 17, 2026
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
March 16, 2026
Myriad Commercially Launches Precise MRD with Select Community Oncologists
March 2, 2026
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
February 23, 2026
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
February 23, 2026
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
February 19, 2026
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
February 16, 2026
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
January 27, 2026
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
January 12, 2026
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
December 8, 2025
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
November 25, 2025
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
November 10, 2025
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
November 9, 2025
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
November 5, 2025
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
November 2, 2025
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
October 30, 2025
Neogen® Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer
October 30, 2025
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
October 26, 2025
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
October 13, 2025
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
October 8, 2025
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
September 22, 2025
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
September 22, 2025
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
September 3, 2025
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
September 2, 2025
ANGLE Announces Collaboration with Myriad Genetics
August 20, 2025
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
August 17, 2025
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
August 12, 2025
RxPreferred Benefits Expands Executive Leadership Team with Strategic Appointment and Key Promotions
August 12, 2025
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
August 6, 2025
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
August 5, 2025